STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
about
P1343
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsSomatic DNA mutation analysis in targeted therapy of solid tumoursReview article: the biology, diagnosis and management of gastrointestinal stromal tumoursHyperplasia of interstitial cells of cajal in sprouty homolog 4 deficient miceStructure of an Unprecedented G-Quadruplex Scaffold in the Human c-kit PromoterA G-Rich Sequence within the c-kit Oncogene Promoter Forms a Parallel G-Quadruplex Having Asymmetric G-Tetrad DynamicsSolution structures of all parallel-stranded monomeric and dimeric G-quadruplex scaffolds of the human c-kit2 promoterKIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorp53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentAn anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumourUpdate on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motilityTargeted therapy for cancer: the gastrointestinal stromal tumor model.Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell lineNeurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal.Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsTargeting G-quadruplexes in gene promoters: a novel anticancer strategy?Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapyImatinib mesylate, the first molecularly targeted gene suppressor.Oncogenes in melanoma.Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy.Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan.
P2860
Q26740953-BED0AFDD-1B67-4792-9111-894DA09AA794Q26770324-5F749C1E-831E-4148-AC59-C3CC77BE65B1Q26825310-0BD7F7BB-0514-426E-8C52-71EACB2676CFQ27308910-8C7B2F26-8614-4B73-90D4-902673C419AAQ27644075-D188C499-7432-48E6-B617-0BB603AC1FA7Q27657150-0192685A-6574-432B-AF47-BEA050EB67FCQ27662546-4DE16830-9CEA-4E6A-98F2-3C8D130D5549Q27824783-490FB649-9AD5-4131-91B3-BEF8D91A3880Q27851455-A190D1D4-4D4F-42B6-AA05-E83BF9D40189Q28483922-644CC03D-5DD3-402F-8C10-BD7DF77F9D9EQ28533949-E3CA340D-5804-47B8-8EA3-C3132C408959Q33308713-BF383B39-240B-42C0-AFE4-F951716D5164Q33639728-DCD8D213-F791-49C7-8DC1-82D9A1673045Q33644791-0D759366-1AE3-416A-965F-C426D5D88957Q33797591-E8AAB46A-D8B5-4241-A64E-C9DBD423A11CQ33807742-4EA44A38-C87A-4AF5-B9C3-1345BEF19142Q33825096-1FB5549B-030C-41E7-A96B-608A14C3B979Q33833577-622235FE-478E-4685-92E9-F274D9B6F04AQ33836021-FC188C1C-B8DB-471A-AB32-A507886FF51FQ33840444-C52EFEC3-E0EB-4806-97A7-5D13BD91FDC3Q33921067-7581E72F-BEB4-4950-AEB9-79875849B19CQ34050275-851FECD3-E676-4FD7-A80A-A911EB520789Q34100865-3B4A857F-0061-4C6A-B0BC-AC38BB6B1C9FQ34174883-4FE98A35-D39A-49B2-9A84-0FF8F64265BEQ34208611-E6C034E2-FD09-4D24-807B-684A159E5FE4Q34289180-341DDFA7-AFC5-4E31-84DF-71E07451C86EQ34344121-F8874C84-6CBE-4558-A01F-9A2B95D4BBEBQ34486028-7C3F6AEE-B031-4259-B3B4-7836A2F0C182Q34518436-059316B9-56FB-41BF-B7B6-C447851A3D0EQ34533831-D7DEAE06-BFB6-4AB1-94D3-12B28B60AC6AQ34550403-80D03FF2-95E5-4614-9DF6-7B37DFEF7854Q34597216-E76475D7-44A0-4711-9309-A229CF042857Q34620856-6D041BF3-CC86-40EE-B70A-A537BD2B6B86Q34674928-2354E3F9-2F2E-4D29-9616-040D92E18B84Q34975667-0F0F474F-0019-4FDF-B8A7-A29372EF5DB2Q35146560-20147131-6700-4737-9F72-A0017A85812FQ35553853-79972B19-1B8B-460D-A43F-189DA36B3F04Q35586732-9BFFD113-C243-4910-93C4-973F1C311608Q35607790-FBA8B157-D001-41EA-8BFE-4CC98B91395BQ35626506-C7600092-9A82-4782-A906-CB6926F995C5
P2860
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
STI571 inactivation of the gas ...... cal and clinical implications.
@en
type
label
STI571 inactivation of the gas ...... cal and clinical implications.
@en
prefLabel
STI571 inactivation of the gas ...... cal and clinical implications.
@en
P2093
P2860
P356
P1433
P1476
STI571 inactivation of the gas ...... cal and clinical implications.
@en
P2093
Demetri GD
Fletcher CD
Fletcher JA
Griffin JD
Tuveson DA
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204704
P407
P4510
P577
2001-08-01T00:00:00Z
P5875
P6179
1036226058